Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


Virologic, immunologic and clinical responses in foreign-born versus US-born HIV-1 infected adults initiating antiretroviral therapy: an observational cohort study.

Parrish DD, Blevins M, Stinnette SE, Rebeiro PF, Shepherd BE, Sterling TR, McGowan CC, Wester CW.

PLoS One. 2012;7(12):e52336. doi: 10.1371/journal.pone.0052336. Epub 2012 Dec 19.


Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons.

Alves TP, Wu P, Ikizler TA, Sterling TR, Stinnette SE, Rebeiro PF, Ghosh S, Hulgan T.

Clin Nephrol. 2013 Feb;79(2):93-100. doi: 10.5414/CN107390.


Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care.

Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Turner MM, Sterling TR.

PLoS One. 2012;7(9):e44999. doi: 10.1371/journal.pone.0044999. Epub 2012 Sep 13.


An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.

Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR.

Clin Infect Dis. 2011 Nov;53(9):952-60. doi: 10.1093/cid/cir606. Epub 2011 Sep 26.


Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting.

Wester CW, Koethe JR, Shepherd BE, Stinnette SE, Rebeiro PF, Kipp AM, Hong H, Bussmann H, Gaolathe T, McGowan CC, Sterling TR, Marlink RG.

AIDS. 2011 Jul 31;25(12):1471-9. doi: 10.1097/QAD.0b013e328347f9d4.


Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts.

McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, Sterling TR, Moore RD, Hulgan T.

PLoS One. 2011 Apr 25;6(4):e18462. doi: 10.1371/journal.pone.0018462.


Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR.

J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):305-10. doi: 10.1097/QAI.0b013e3182182e2d.


The relationship between injection and noninjection drug use and HIV disease progression.

Qian HZ, Stinnette SE, Rebeiro PF, Kipp AM, Shepherd BE, Samenow CP, Jenkins CA, No P, McGowan CC, Hulgan T, Sterling TR.

J Subst Abuse Treat. 2011 Jul;41(1):14-20. doi: 10.1016/j.jsat.2011.01.007. Epub 2011 Feb 23.


Race, kidney disease progression, and mortality risk in HIV-infected persons.

Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2269-75. doi: 10.2215/CJN.00520110. Epub 2010 Sep 28.


Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy.

Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR.

Epidemiology. 2010 Sep;21(5):698-705. doi: 10.1097/EDE.0b013e3181e97737.


Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.

Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR.

AIDS Patient Care STDS. 2010 May;24(5):279-86. doi: 10.1089/apc.2009.0283.


Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response.

Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Barkanic G, Raffanti SP, Sterling TR.

PLoS One. 2009 Sep 9;4(9):e6961. doi: 10.1371/journal.pone.0006961.


Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures.

Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, Sterling TR, Raffanti SP, D'Aquila RT.

Clin Infect Dis. 2008 Nov 15;47(10):1354-7. doi: 10.1086/592693.

Supplemental Content

Loading ...
Support Center